Home Newsletters Hematopoiesis News Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (Apadamtase Alfa /Cinaxadamtase Alfa)...

Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (Apadamtase Alfa /Cinaxadamtase Alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

By
Noshin Noorjahan
-
0
Takeda announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of ADZYNMA for the treatment of cTTP for individuals 12 years of age and older.
[Takeda]
Press Release

RELATED ARTICLES

Exit mobile version